STOCK TITAN

Cytokinetics (CYTK) Stock News, May 6-7, 2020

CYTK NASDAQ

Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.

Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) announced its Annual Meeting of Stockholders on May 13, 2020, at 10:30 AM PT in South San Francisco. Due to COVID-19, safety measures including masks and temperature checks will be implemented. Stockholders of record by March 23, 2020, are eligible to vote either in person or via proxy until May 12, 2020, at 11:59 PM ET. A live webcast of the meeting and subsequent CEO presentation will be available on the company's website. Cytokinetics focuses on developing innovative muscle activators and inhibitors for diseases that affect muscle performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

Cytokinetics, incorporated (NASDAQ: CYTK) reported a net loss of $39.4 million, or $0.66 per share for Q1 2020, compared to a loss of $29.4 million, or $0.54 per share in Q1 2019. Cash, cash equivalents, and investments stand at $237.2 million, providing a runway of over two years based on expected spending of $105-115 million in 2020. The company anticipates top-line results from the GALACTIC-HF trial in Q4 2020 and continues to prioritize clinical programs despite COVID-19 related challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags

FAQ

What is the current stock price of Cytokinetics (CYTK)?

Cytokinetics (CYTK) last closed at $50.78.

What is the market cap of Cytokinetics (CYTK)?

The market cap of Cytokinetics (CYTK) is approximately $7.1B.